UAE Geneticist Solves Medical Mystery with Discovery of New Rare Disorder
For numerous families across the United Arab Emirates, a distressing medical journey marked by developmental delays and unexplained muscle weakness in their children had reached a frustrating dead end. Standard genetic tests repeatedly returned normal results, leaving parents anxious, children confused, and medical professionals thoroughly baffled by an invisible condition they could not even identify.
The Diagnostic Breakthrough
This is precisely when Dr. Ayman El-Hattab, a distinguished geneticist based in the UAE, intervened with dedicated perseverance. His relentless efforts ultimately led to the identification of a previously unknown rare genetic disorder, which has since gained international recognition and been formally named after its discoverers.
The El-Hattab-Schmidt syndrome was first documented in 2018 after clinicians observed children exhibiting strikingly similar neurological features, all sharing a mutation in a specific gene that had never before been associated with human disease. At that time, no existing medical literature linked defects in this particular gene to any known condition.
"All the genes we typically test were normal," explained Dr. Ayman W. El-Hattab, Consultant Clinical Genetics and Director of the Genetics and Rare Disease Centre at Burjeel Medical City. "So, we started looking beyond what was already known, venturing into uncharted genetic territory."
International Recognition and Validation
Dr. El-Hattab and his research team meticulously investigated these cases, publishing their initial groundbreaking findings in 2018. They documented children with overlapping clinical presentations and identical mutations in the same gene. Subsequently, independent researchers in Europe reported strikingly similar cases, providing crucial external validation.
As more evidence accumulated from different parts of the world, the medical community formally recognized this as a distinct new syndrome. It was officially listed in the OMIM international genetics database under the designation 'El-Hattab-Schmidt' syndrome, appropriately crediting both research groups that had independently identified it.
Understanding El-Hattab-Schmidt Syndrome
The El-Hattab-Schmidt syndrome is primarily neurological in nature, most commonly manifesting in affected children through developmental delay and significant muscle weakness. While these symptoms individually are not unique, they become medically significant when consistently linked to the same specific genetic mutation.
"None of the symptoms are specific by themselves," Dr. El-Hattab clarified. "What ultimately defined this as a new syndrome was discovering the identical genetic defect in multiple children who presented with similar clinical features."
The syndrome follows an autosomal recessive inheritance pattern, meaning both parents must carry the gene mutation for a child to be affected. Each pregnancy consequently carries a 25% risk of having a child with the condition. With a confirmed diagnosis now possible, families can explore reproductive options such as in-vitro fertilization with embryo testing to prevent recurrence in future pregnancies.
"Without knowing the genetic cause, you cannot prevent it," emphasized Professor El-Hattab. "Once you identify it definitively, everything changes for affected families."
Clinical Implications and Future Directions
Although no targeted treatment currently exists for El-Hattab-Schmidt syndrome, its formal identification has initiated crucial medical progress. Once a condition is properly named and clinically described, healthcare providers can anticipate potential complications and deliver more structured, proactive care rather than working blindly.
"If we understand that a syndrome may potentially affect the eyes, we can arrange regular ophthalmological examinations," Dr. El-Hattab elaborated. "If it is associated with hearing impairment, cardiac issues, or hormonal abnormalities, we can monitor those systems proactively before problems escalate."
Substantial research has continued following the syndrome's identification. A major case series published in January 2026 revealed the total number of reported patients worldwide had reached 24 individuals. According to Dr. El-Hattab, the actual prevalence is likely higher, considering that global access to advanced genetic testing remains uneven and many cases probably go unreported.
As more previously unknown genetic conditions are identified through similar diagnostic odysseys, Dr. El-Hattab believes earlier and more accurate diagnoses will become increasingly feasible, sparing future families years of uncertainty and diagnostic frustration.
"This is precisely how meaningful medical progress begins," he reflected. "First you understand the underlying genetic defect, then you investigate how to treat it—whether through pharmaceutical interventions, supportive therapies, or eventually advanced gene-based therapeutic approaches."
